Carlos Alexander Huertas-Caro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carlos Alexander Huertas-Caro has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Laura Rey-Vargas
Instituto Nacional de Cancerologia
3 shared publications - Alfonso J. Rodriguez-Morales
Faculty of Health Sciences, Universidad Científica del Sur, Lima 15067, Peru
2 shared publications - Carlos Eduardo Jiménez-Canizales
Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia
2 shared publications - Diana Carolina Urrego
Ministerio de Salud y Protección Social, Colombia
2 shared publications - Diego Felipe Ballen
Instituto Nacional de Cancerologia
2 shared publications - Gina Hurtado
Deputy Directorate of Operations Management, Ministry of Health and Social Protection, Bogotá 110311, Colombia
2 shared publications
Latest Publications
- Open Access
Adverse Events Following Yellow Fever Vaccination in Older Adults in Colombia, 2024–2025: A National Pharmacovigilance Analysis
Introduction: Yellow fever re-emerged as a major public health threat in the Americas during 2024–2025, with increasing numbers of cases and deaths, predominantly among unvaccinated individuals. Although the live-attenuated 17D yellow fever vaccine is highly effective, adults aged ≥60 years have an increased risk of serious adverse events following immunization (AEFIs). We assessed the safety profile of yellow fever vaccination in Colombia, with particular emphasis on older adults, and contextualized the observed risks within an epidemic setting characterized by active transmission and high mortality. Methods: We conducted an observational, descriptive study using secondary data from Colombia’s Expanded Program on Immunization and the national VigiFlow pharmacovigilance system. Individuals vaccinated against yellow fever between 1 October 2024 and 31 July 2025 were included. We analyzed reported AEFIs by seriousness, sex, and age group. We calculated rates per 100,000 vaccinated individuals with 95% confidence intervals and compared them between adults aged ≥60 years and younger individuals. We further stratified older adults into five-year age groups. Results: Among 3,915,966 vaccinated individuals, 425 AEFIs were reported in 233 unique cases. The overall AEFI reporting rate was 10.85 per 100,000 vaccinated individuals, and the serious AEFI reporting rate was 2.94 per 100,000. Adults aged ≥60 years had substantially higher overall AEFI reporting rates than those aged <60 years (54.05 versus 6.12 per 100,000, respectively), corresponding to a rate ratio of 8.8. Serious AEFI reporting rates were 11.90 and 1.96 per 100,000, respectively, corresponding to a rate ratio of 6.1. The highest serious AEFI reporting rate was observed among adults aged 80–84 years, at 49.82 per 100,000. Nine fatal outcomes were reported; following causality assessment, none was considered attributable to the vaccine. Conclusions: Reported AEFIs following yellow fever vaccination were more frequent among adults aged ≥60 years, with a particularly marked increase in the oldest age groups. Nevertheless, the absolute serious AEFI reporting rate remained low, at approximately 1.2 per 10,000 vaccinated older adults, and no reviewed fatal outcomes were attributed to vaccination. In settings of active yellow fever transmission, vaccination decisions for older adults should therefore be guided by individualized benefit–risk assessment rather than age alone, accompanied by careful screening, active pharmacovigilance, and clear risk communication. Vaccination remains the principal intervention for preventing yellow fever-related deaths.
Open AccessAdverse Events Following Yellow Fever Vaccination in Older Adults in Colombia, 2024–2025: A National Pharmacovigilance Analysis
Introduction: Yellow fever re-emerged as a major public health threat in the Americas during 2024–2025, with increasing numbers of cases and deaths, predominantly among unvaccinated individuals. Although the live-attenuated 17D yellow fever vaccine is highly effective, adults aged ≥60 years have an increased risk of serious adverse events following immunization (AEFIs). We assessed the safety profile of yellow fever vaccination in Colombia, with particular emphasis on older adults, and contextualized the observed risks within an epidemic setting characterized by active transmission and high mortality. Methods: We conducted an observational, descriptive study using secondary data from Colombia’s Expanded Program on Immunization and the national VigiFlow pharmacovigilance system. Individuals vaccinated against yellow fever between 1 October 2024 and 31 July 2025 were included. We analyzed reported AEFIs by seriousness, sex, and age group. We calculated rates per 100,000 vaccinated individuals with 95% confidence intervals and compared them between adults aged ≥60 years and younger individuals. We further stratified older adults into five-year age groups. Results: Among 3,915,966 vaccinated individuals, 425 AEFIs were reported in 233 unique cases. The overall AEFI reporting rate was 10.85 per 100,000 vaccinated individuals, and the serious AEFI reporting rate was 2.94 per 100,000. Adults aged ≥60 years had substantially higher overall AEFI reporting rates than those aged <60 years (54.05 versus 6.12 per 100,000, respectively), corresponding to a rate ratio of 8.8. Serious AEFI reporting rates were 11.90 and 1.96 per 100,000, respectively, corresponding to a rate ratio of 6.1. The highest serious AEFI reporting rate was observed among adults aged 80–84 years, at 49.82 per 100,000. Nine fatal outcomes were reported; following causality assessment, none was considered attributable to the vaccine. Conclusions: Reported AEFIs following yellow fever vaccination were more frequent among adults aged ≥60 years, with a particularly marked increase in the oldest age groups. Nevertheless, the absolute serious AEFI reporting rate remained low, at approximately 1.2 per 10,000 vaccinated older adults, and no reviewed fatal outcomes were attributed to vaccination. In settings of active yellow fever transmission, vaccination decisions for older adults should therefore be guided by individualized benefit–risk assessment rather than age alone, accompanied by careful screening, active pharmacovigilance, and clear risk communication. Vaccination remains the principal intervention for preventing yellow fever-related deaths.
- Open Access
- 10 August 2026
- Published by MDPI AG in Preprints.org
Yellow Fever Vaccination in Older Adults During the 2024–2025 Outbreak in Colombia: National Safety Surveillance and a Benefit–Risk Perspective
Introduction: Yellow fever re-emerged as a major public health threat in the Americas during 2024–2025, with increasing numbers of cases and deaths, predominantly among unvaccinated individuals. Although the live-attenuated 17D yellow fever vaccine is highly effective, adults aged ≥60 years have an increased risk of serious adverse events following immunization (AEFIs). We assessed the safety profile of yellow fever vaccination in Colombia, with particular emphasis on older adults, and contextualized the observed risks within an epidemic setting characterized by active transmission and high mortality. Methods: We conducted an observational, descriptive study using secondary data from Colombia’s Expanded Program on Immunization and the national VigiFlow pharmacovigilance system. Individuals vaccinated against yellow fever between October 1, 2024, and July 31, 2025, were included. Reported AEFIs were analyzed by severity, sex, and age group. Rates were calculated per 100,000 vaccinated individuals, with 95% confidence intervals, and compared between adults aged ≥60 years and younger individuals. Older adults were further stratified into five-year age groups. Results: Among 3,915,966 vaccinated individuals, 425 AEFIs were reported in 233 unique cases. The overall AEFI rate was 10.85 per 100,000 vaccinated individuals, and the severe AEFI rate was 2.94 per 100,000. Adults aged ≥60 years had substantially higher rates of overall AEFIs than those aged Conclusions: Reported AEFIs following yellow fever vaccination were more frequent among adults aged ≥60 years, with a particularly marked increase in the oldest age groups. Nevertheless, the absolute rate of severe events remained low, at approximately 1.2 per 10,000 vaccinated older adults, and no reviewed fatal outcomes were attributed to vaccination. In settings of active yellow fever transmission, vaccination decisions for older adults should therefore be guided by individualized benefit–risk assessment rather than age alone, accompanied by careful screening, active pharmacovigilance, and clear risk communication. Vaccination remains the principal intervention for preventing yellow fever-related deaths.
- 10 August 2026
- Published by MDPI AG in Preprints.org
Open AccessYellow Fever Vaccination in Older Adults During the 2024–2025 Outbreak in Colombia: National Safety Surveillance and a Benefit–Risk Perspective
Introduction: Yellow fever re-emerged as a major public health threat in the Americas during 2024–2025, with increasing numbers of cases and deaths, predominantly among unvaccinated individuals. Although the live-attenuated 17D yellow fever vaccine is highly effective, adults aged ≥60 years have an increased risk of serious adverse events following immunization (AEFIs). We assessed the safety profile of yellow fever vaccination in Colombia, with particular emphasis on older adults, and contextualized the observed risks within an epidemic setting characterized by active transmission and high mortality. Methods: We conducted an observational, descriptive study using secondary data from Colombia’s Expanded Program on Immunization and the national VigiFlow pharmacovigilance system. Individuals vaccinated against yellow fever between October 1, 2024, and July 31, 2025, were included. Reported AEFIs were analyzed by severity, sex, and age group. Rates were calculated per 100,000 vaccinated individuals, with 95% confidence intervals, and compared between adults aged ≥60 years and younger individuals. Older adults were further stratified into five-year age groups. Results: Among 3,915,966 vaccinated individuals, 425 AEFIs were reported in 233 unique cases. The overall AEFI rate was 10.85 per 100,000 vaccinated individuals, and the severe AEFI rate was 2.94 per 100,000. Adults aged ≥60 years had substantially higher rates of overall AEFIs than those aged Conclusions: Reported AEFIs following yellow fever vaccination were more frequent among adults aged ≥60 years, with a particularly marked increase in the oldest age groups. Nevertheless, the absolute rate of severe events remained low, at approximately 1.2 per 10,000 vaccinated older adults, and no reviewed fatal outcomes were attributed to vaccination. In settings of active yellow fever transmission, vaccination decisions for older adults should therefore be guided by individualized benefit–risk assessment rather than age alone, accompanied by careful screening, active pharmacovigilance, and clear risk communication. Vaccination remains the principal intervention for preventing yellow fever-related deaths.
- Open Access
- 17 February 2026
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 13 (1-Supl) , 72-84
Epidemiología molecular: el papel del Atlas del Genoma del Cáncer a lo largo de la historia
Introducción: el Atlas del Genoma del Cáncer (TCGA) ha sido un proyecto colaborativo internacional y multiinstitucional diseñado para caracterizar de manera integral las alteraciones moleculares de tumores de alta relevancia clínica. Este trabajo resume sus principales aportes, así como las limitaciones y retos derivados de su implementación. Métodos: se realizó una búsqueda estructurada en PubMed, EMBASE y Web of Science sobre TCGA, incluyendo publicaciones relacionadas con sus resultados, metodología, limitaciones y repercusiones clínicas y traslacionales. Resultados: se identificaron 88 publicaciones relevantes. TCGA analizó más de 20.000 muestras correspondientes a 33 tipos tumorales, integrando datos genómicos, transcriptómicos, epigenómicos y proteómicos. Entre sus contribuciones más relevantes destacan: a) la redefinición de la clasificación tumoral mediante subtipos moleculares, b) la identificación de mutaciones y vías de señalización con impacto terapéutico, como IDH1 en gliomas y subtipos moleculares en cáncer de mama, endometrio y estómago, c) la validación de biomarcadores pronósticos y predictivos, y d) el desarrollo de bases de datos abiertas que impulsaron estudios traslacionales y ensayos clínicos tipo canasta. En 2018, el Pan-cáncer Atlas evidenció similitudes moleculares transtumorales y consolidó el concepto de “genoma teranóstico”. Persisten limitaciones relacionadas con la representatividad poblacional, la heterogeneidad clínica y la aplicabilidad en entornos con recursos limitados. Conclusión: TCGA representó un hito en la oncología de precisión al transformar la comprensión de la biología tumoral y sentar las bases para el desarrollo de terapias dirigidas. Sus datos continúan siendo un recurso central para la investigación oncológica global.
- 17 February 2026
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 13 (1-Supl) , 72-84
Open AccessEpidemiología molecular: el papel del Atlas del Genoma del Cáncer a lo largo de la historia
Introducción: el Atlas del Genoma del Cáncer (TCGA) ha sido un proyecto colaborativo internacional y multiinstitucional diseñado para caracterizar de manera integral las alteraciones moleculares de tumores de alta relevancia clínica. Este trabajo resume sus principales aportes, así como las limitaciones y retos derivados de su implementación. Métodos: se realizó una búsqueda estructurada en PubMed, EMBASE y Web of Science sobre TCGA, incluyendo publicaciones relacionadas con sus resultados, metodología, limitaciones y repercusiones clínicas y traslacionales. Resultados: se identificaron 88 publicaciones relevantes. TCGA analizó más de 20.000 muestras correspondientes a 33 tipos tumorales, integrando datos genómicos, transcriptómicos, epigenómicos y proteómicos. Entre sus contribuciones más relevantes destacan: a) la redefinición de la clasificación tumoral mediante subtipos moleculares, b) la identificación de mutaciones y vías de señalización con impacto terapéutico, como IDH1 en gliomas y subtipos moleculares en cáncer de mama, endometrio y estómago, c) la validación de biomarcadores pronósticos y predictivos, y d) el desarrollo de bases de datos abiertas que impulsaron estudios traslacionales y ensayos clínicos tipo canasta. En 2018, el Pan-cáncer Atlas evidenció similitudes moleculares transtumorales y consolidó el concepto de “genoma teranóstico”. Persisten limitaciones relacionadas con la representatividad poblacional, la heterogeneidad clínica y la aplicabilidad en entornos con recursos limitados. Conclusión: TCGA representó un hito en la oncología de precisión al transformar la comprensión de la biología tumoral y sentar las bases para el desarrollo de terapias dirigidas. Sus datos continúan siendo un recurso central para la investigación oncológica global.
- Open Access
- 17 February 2026
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 13 (1-Supl) , 425-449
Relación de la ancestría genética en las alteraciones moleculares en distintos modelos de cáncer
Introducción: las disparidades en cáncer se han atribuido principalmente a determinantes sociales y factores del estilo de vida, sin embargo, evidencia reciente sugiere que la ancestría genética también puede influir en la biología tumoral. Comprender esta relación es clave para avanzar hacia una medicina de precisión más equitativa. Métodos: se realizó una revisión de la literatura mediante PubMed sin restricciones temporales. Se incluyeron estudios originales que evaluaran la asociación entre la ancestría genética, inferida a partir de marcadores genómicos, y alteraciones moleculares en distintos tipos de cáncer, excluyendo aquellos basados únicamente en autoidentificación étnica. Resultados: cuarenta estudios cumplieron los criterios de inclusión. Los cánceres más representados fueron mama, pulmón, colon, próstata y neoplasias hematológicas. En cáncer de mama, la ancestría africana se asoció con mutaciones en TP53 y activación de las vías NFκB y EGFR, mientras que la ancestría europea se asoció con mutaciones en PIK3CA y PTEN. En cáncer de pulmón, la ancestría asiática mostró alta prevalencia de mutaciones en EGFR y fusiones de ALK. En cáncer colorrectal, la ancestría africana se asoció con alteraciones en KRAS y APC, y la europea con BRAF y CHEK2. Además, se identificaron asociaciones específicas en cáncer de próstata y leucemia linfoblástica aguda. Conclusión: la evidencia disponible respalda que la ancestría genética influye en los perfiles moleculares tumorales y puede contribuir a explicar las disparidades en cáncer. Sin embargo, aún persiste una subrepresentación de grupos con alta ancestría nativa americana, como la latinoamericana, lo que limita la equidad en la medicina de precisión.
- 17 February 2026
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 13 (1-Supl) , 425-449
Open AccessRelación de la ancestría genética en las alteraciones moleculares en distintos modelos de cáncer
Introducción: las disparidades en cáncer se han atribuido principalmente a determinantes sociales y factores del estilo de vida, sin embargo, evidencia reciente sugiere que la ancestría genética también puede influir en la biología tumoral. Comprender esta relación es clave para avanzar hacia una medicina de precisión más equitativa. Métodos: se realizó una revisión de la literatura mediante PubMed sin restricciones temporales. Se incluyeron estudios originales que evaluaran la asociación entre la ancestría genética, inferida a partir de marcadores genómicos, y alteraciones moleculares en distintos tipos de cáncer, excluyendo aquellos basados únicamente en autoidentificación étnica. Resultados: cuarenta estudios cumplieron los criterios de inclusión. Los cánceres más representados fueron mama, pulmón, colon, próstata y neoplasias hematológicas. En cáncer de mama, la ancestría africana se asoció con mutaciones en TP53 y activación de las vías NFκB y EGFR, mientras que la ancestría europea se asoció con mutaciones en PIK3CA y PTEN. En cáncer de pulmón, la ancestría asiática mostró alta prevalencia de mutaciones en EGFR y fusiones de ALK. En cáncer colorrectal, la ancestría africana se asoció con alteraciones en KRAS y APC, y la europea con BRAF y CHEK2. Además, se identificaron asociaciones específicas en cáncer de próstata y leucemia linfoblástica aguda. Conclusión: la evidencia disponible respalda que la ancestría genética influye en los perfiles moleculares tumorales y puede contribuir a explicar las disparidades en cáncer. Sin embargo, aún persiste una subrepresentación de grupos con alta ancestría nativa americana, como la latinoamericana, lo que limita la equidad en la medicina de precisión.
- Open Access
Comparative Genomic and Microenvironmental Profiles of Hereditary and Sporadic TNBC in Colombian Women
Breast cancer (BC) is a heterogeneous disease, and triple-negative breast cancer (TNBC) is the most aggressive and immunogenic subtype. A significant proportion of TNBC cases are linked to hereditary cancer syndromes involving pathogenic germline variants, most commonly in BRCA1/2. However, few studies have compared hereditary and sporadic TNBC in admixed populations. In this study, molecular and immunological features were analyzed through the analysis of 62 Colombian TNBC samples (20 hereditary and 42 sporadic cases) by RNA sequencing to identify molecular and immune differences. We used an external validation cohort of 16 TCGA TNBC cases (8 BRCA-mutated and 8 non-mutated) to replicate our findings. Results: We found a set of 921 differentially expressed genes (DEGs) between hereditary and sporadic TNBC. Hereditary tumors were enriched for pathways related to extracellular matrix (ECM) remodeling, structural components, and DNA damage response and exhibited a more immunologically active tumor microenvironment compared to sporadic tumors. LASSO logistic regression identified 23 genes with discriminatory potential, showing that hereditary tumors are characterized by complex immune regulation, inflammatory processes, and activation of key oncogenic pathways. Conclusions: Hereditary TNBC is characterized by molecular and biological functions linked to ECM remodeling and its constituents and an active immune microenvironment. This integrated molecular–immune profile provides insight into the distinct biology of hereditary tumors in admixed populations.
Open AccessComparative Genomic and Microenvironmental Profiles of Hereditary and Sporadic TNBC in Colombian Women
Breast cancer (BC) is a heterogeneous disease, and triple-negative breast cancer (TNBC) is the most aggressive and immunogenic subtype. A significant proportion of TNBC cases are linked to hereditary cancer syndromes involving pathogenic germline variants, most commonly in BRCA1/2. However, few studies have compared hereditary and sporadic TNBC in admixed populations. In this study, molecular and immunological features were analyzed through the analysis of 62 Colombian TNBC samples (20 hereditary and 42 sporadic cases) by RNA sequencing to identify molecular and immune differences. We used an external validation cohort of 16 TCGA TNBC cases (8 BRCA-mutated and 8 non-mutated) to replicate our findings. Results: We found a set of 921 differentially expressed genes (DEGs) between hereditary and sporadic TNBC. Hereditary tumors were enriched for pathways related to extracellular matrix (ECM) remodeling, structural components, and DNA damage response and exhibited a more immunologically active tumor microenvironment compared to sporadic tumors. LASSO logistic regression identified 23 genes with discriminatory potential, showing that hereditary tumors are characterized by complex immune regulation, inflammatory processes, and activation of key oncogenic pathways. Conclusions: Hereditary TNBC is characterized by molecular and biological functions linked to ECM remodeling and its constituents and an active immune microenvironment. This integrated molecular–immune profile provides insight into the distinct biology of hereditary tumors in admixed populations.